Muscarinic receptor subtype distribution in the central nervous system and relevance to aging and Alzheimer's disease.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or meta-analytic methods.
PubMed 29138080 · doi:10.1016/j.neuropharm.2017.11.018
What was done
This narrative review synthesized literature on the distribution of muscarinic acetylcholine receptor subtypes (M1–M5) across central nervous system cell types and evaluated their relevance as therapeutic targets in aging, amnestic mild cognitive impairment, and Alzheimer's disease, alongside methodological approaches used for receptor mapping.
What was found
The abstract reports no quantitative data or numerical outcomes. It describes how previous mapping relied primarily on radioligands with modest subtype selectivity and identifies the ongoing need for subtype-selective small molecule radioligands, validated commercial antibodies, and novel genetic tools.
Why it matters
Clarifying subtype-specific muscarinic receptor localization helps guide the rational design of selective therapeutics for neurodegenerative diseases while outlining key methodological limitations in historical receptor profiling.
Limits
This is a non-systematic narrative review containing no primary experimental data or quantitative synthesis. The discussed evidence is historically limited by low pharmacological and immunological subtype selectivity.
Cited by
- supports There are five distinct subtypes of muscarinic acetylcholine receptors.